Methods of treating breast cancer using 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
WO2011153382A1
Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and platinum compound
TW201206449A
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
TW201206448A
Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
CA2725026A1
Methods of treating platinum-sensitive recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
CA2725027A1
Methods of treating platinum-resistant recurrent ovarian cancer with 4-iodo-3-nitrobenzamide in combination with an anti-metabolite and a platinum compound
TN2010000232A1
Formulations for cancer treatment
US2010279327A1
Method of treating diseases with parp inhibitors
CN102307475A
Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor
US2009275608A1
Methods of diagnosing and treating parp-mediated diseases
MX2010006154A
Treatment of cancer with combinations of topoisomerase inhibitors and parp inhibitors.
WO2009064444A2
Treatment of uterine cancer and ovarian cancer with a parp inhibitor alone or in combination with anti-tumor agents
UA99934C2
Method of treating breast cancer with use of 4-iodo-3-nitrobenzamide in combination with anti-tumor agents
NZ586125A
Treatment of breast cancer with a parp inhibitor alone or in combination with anti-tumor agents
WO2009051815A1
Methods and compositions for the treatment of cancer using benzopyrone-type parp inhibitors
NZ579098A
Formulations for cancer treatment
US2008262062A1
Method of treating diseases with parp inhibitors
CN102379884A
Inhibition of fatty acid synthesis by PARP inhibitors and methods of treatment thereof
